Bioventus Inc.
General ticker "BVS" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $569.5M (TTM average)
Bioventus Inc. follows the US Stock Market performance with the rate: 49.3%.
Estimated limits based on current volatility of 2.5%: low 13.31$, high 13.99$
Factors to consider:
- Total employees count: 930 (0.0%) as of 2025
- US accounted for 41.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Liquidity and credit risks, Product development failure, Strategic risks and growth management, Acquisition/divestiture risks, Market competition
- Current price 23.0% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.33$, 10.81$]
- 2026-12-31 to 2027-12-31 estimated range: [7.13$, 12.01$]
Financial Metrics affecting the BVS estimates:
- Positive: with PPE of 11.0 at the end of fiscal year the price was neutral
- Positive: 11.37 < Operating cash flow per share per price, % of 15.01
- Positive: 7.80 < Operating profit margin, % of 9.50
- Positive: -1.23 < Investing cash flow per share per price, % of -0.65
- Positive: 3.48 < Return on assets ratio (scaled to [-100,100]) of 3.84
- Negative: Industry earnings per price (median), % of -3.46 <= 0
- Positive: Interest expense per share per price, % of 5.32 <= 10.35
Short-term BVS quotes
Long-term BVS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $508.77MM | $573.28MM | $568.01MM |
| Operating Expenses | $590.49MM | $585.26MM | $514.03MM |
| Operating Income | $-81.72MM | $-11.98MM | $53.98MM |
| Non-Operating Income | $-39.39MM | $-37.15MM | $-28.27MM |
| Interest Expense | $40.68MM | $38.79MM | $26.49MM |
| R&D Expense | $13.45MM | $13.95MM | $12.11MM |
| Income(Loss) | $-121.11MM | $-49.13MM | $25.71MM |
| Taxes | $0.09MM | $-5.29MM | $-1.56MM |
| Other Income(Loss) | $-74.43MM | $0.00MM | $0.00MM |
| Net Income(Loss)* | $-156.23MM | $-33.54MM | $22.73MM |
| Stockholders Equity | $173.59MM | $147.94MM | $184.10MM |
| Inventory | $91.33MM | $92.47MM | $82.24MM |
| Assets | $810.91MM | $727.96MM | $683.56MM |
| Operating Cash Flow | $15.34MM | $38.80MM | $74.67MM |
| Capital expenditure | $7.36MM | $1.01MM | $2.56MM |
| Investing Cash Flow | $15.81MM | $22.96MM | $-3.25MM |
| Financing Cash Flow | $-26.65MM | $-54.58MM | $-62.14MM |
| Earnings Per Share** | $-2.49 | $-0.51 | $0.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.